Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada

Authors

  • Danalyn Byng York University

DOI:

https://doi.org/10.25071/1929-8404.34702

Abstract

This paper was prepared for a course on Canadian health policy. Its purpose is to expose the harmful ramifications of international trade agreements on the pharmaceutical market in Canada and the governance surrounding this market. This paper will explore the various implications that trade agreements have on the affordability of drugs, the strength of intellectual property protection, and the transfer of authority and influence from government to “Big Pharma.” This paper will unravel the reality that trade agreements are not beneficial to the Canadian people looking to access an affordable pharmaceutical market, but rather, act quite contrary to this. Facts will show that trade agreements work to put money into the pockets of large brand-name pharmaceutical companies in the forms of billions of dollars of revenue and profit. This paper will encourage readers to question the feasibility of extending patent legislation for brand-name pharmaceutical products, the increasing role of trade agreements and the pharmaceutical industry in Canada, and the substitutability of brand-name drugs over cheaper generic alternatives.

References

Abbot, F. (2006). The Cycle of Action and Redaction: Developments and Trends in Intellectual Property and Health. In P. Roffe, G. Tansey & D. Vivas-Eugui (Eds.), Negotiating Health: Intellectual Property and Access to Medicines (27-40). London: Earthscan.

Armstrong, P. & Armstrong, H. (1991). Health Care as a Business: The legacy of free trade. Ottawa: Canadian Centre for Policy Alternatives.

Canadian Institute for Health Information. (2010). Drug Expenditure in Canada, 1985-2010 [Data file]. Retrieved from http://secure.cihi.ca/cihiweb/products/drug_expenditure_2010_en.pdf

Grieshaber-Otto, J. & Sinclair, S. (2004). Key trade treaty rules and health safeguards. In Bad Medicine (chapter 2). Retrieved from http://www.policyalternatives.ca/sites/default/files/uploads/publications/National_Office_Pubs/bad_medicine.pdf

Grootendorst, P. (2009). Patents, public-private partnerships or prizes: How should we support pharmaceutical innovation? Hamilton, ON: Program for Research on Social and Economic Dimensions of an Aging Population, McMaster University.

Grootendorst, P. & Hollis, A. (2011, February 7). The Canadian-European Union Comprehensive Economic & Trade Agreement: An economic impact assessment of proposed pharmaceutical intellectual property provisions. Retrieved from http://www.canadiangenerics.ca/en/news/docs/02.07.11CETAEconomicImpactAssessment-FinalEnglish.pdf

Hore, E. (2004). Patently absurd: Evergreening of pharmaceutical patent protection under the patented medicines (Notice of Compliance) regulations of Canada's Patent Act. Toronto, ON: Canadian Generic Pharmaceutical Association.

Lanjouw, J. (2005). Patents, Price Controls and Access to New Drugs: How policy affects global market entry (National Bureau of Economic Research Working Paper 11321).

Lexchin, J. (1992). Pharmaceuticals, patents and politics: Canada and Bill C-22. Ottawa, ON: The Canadian Centre for Policy Alternatives.

Lexchin, J. (2001). Globalization, trade deals and drugs: Heads the industry wins, tails Canada loses. Canadian Centre for Policy Alternatives Briefing Paper Series: Trade and Investment, 2(8). Retrieved from http://www.policyalternatives.ca/sites/default/files/uploads/publications/National_Office_Pubs/brief2_8.pdf

Lexchin, J. (2005). Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here? International Journal of Health Services, 35(5), 237-56.

Permanand, G. & Altenstetter, C. (2004). The politics of pharmaceuticals in the European Union. In E. Mossialos, M. Mrazek & T. Walley (Eds.), Regulating pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (38-54). Maidenhead: Open University Press.

Pazderka, B. (1999). Patent Protection and Pharmaceutical R&D Spending in Canada. Canadian Public Policy, 25(1), 29-46.

Picard, A. (2011, February 7). EU trade deal could cost Canadian drug plan billions. The Globe and Mail. Retrieved from http://www.theglobeandmail.com/life/health/eu-trade-deal-could-cost-canadian-drug-plans-billions/article1896747/

Romanow, R. J. (2002) Building on Values: The Future of Health Care in Canada. Saskatoon: Commission on the Future of Health Care in Canada.

Smith, M. (2000). Patent protection for pharmaceutical products in Canada: Chronology of significant events. Retrieved from Library of Parliament, Parliamentary Research Branch: http://dsp-psd.communication.gc.ca/Collection-R/LoPBdP/BP/prb9946-e.htm

Downloads

Published

2012-09-04

How to Cite

Byng, D. (2012). Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada. Healthy Dialogue, 1(1). https://doi.org/10.25071/1929-8404.34702

Issue

Section

Health Policy